Delivering on the Promise of Biosimilars.


Journal

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 14 10 2019
medline: 9 4 2020
entrez: 14 10 2019
Statut: ppublish

Résumé

Fifteen years of experience with biosimilar evaluation in Europe and advancement in the science behind biological medicines, provides a timely moment to open up debate as to whether the requirements for biosimilar approval could be further tailored. Further optimizing of data requirements to truly decisional information will allow to continuously deliver on the promise of biosimilars, providing benefits for patients and society.

Identifiants

pubmed: 31606870
doi: 10.1007/s40259-019-00388-9
pii: 10.1007/s40259-019-00388-9
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

599-602

Auteurs

Arnold G Vulto (AG)

Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium. a.vulto@gmail.com.
Hospital Pharmacy, ErasmusMC, Rotterdam, The Netherlands. a.vulto@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH